Would You like a feature Interview?
All Interviews are 100% FREE of Charge
The first major U.S. health insurance company to begin paying for Novo Nordisk’s popular weight-loss injection Wegoby, according to reports. wall street journal An exclusive report was published on Friday.
Kaiser Permanente, Elevance Health and CVS Health’s Aetna insurance division announced in a statement that they will cover the insurance, also known as Wegovy. Semaglutide, reduce the risk of heart attack and stroke. The news comes a week after the U.S. Centers for Medicare and Medicaid Services’ announcement. said Medicare beneficiaries are eligible for Wegoby if it is prescribed to manage heart health.
Related: Popular appetite suppressant Ozempic can be manufactured for less than $5 a month, new study suggests
Coverage of Wegovy will begin immediately for some plans like Kaiser Permanente, while others like Elevance will begin coverage of the drug in the coming weeks.
Wegovy is an injectable prescription weight loss drug. (Photo by Michael Siluk/UCG/Universal Images Group, Getty Images)
Earlier this month, the U.S. Food and Drug Administration approved Heart health research based on global research published last year New England Medical Journal It showed that the drug could reduce the risk of heart attack and stroke by 20%.The drug was previously approved only for diabetes in the United States, according to bloomberg.
The study involved 17,604 people aged 45 and over from 41 countries, who were followed for an average of at least three years. The goal was to investigate how Wegovy affects heart disease and weight, but not diabetes.
Participants who received Wegovy injections weekly lost about 9% of their body weight and saw improvements in blood pressure, blood sugar, cholesterol levels, and inflammation.
Martin Horst Lange, executive vice president and head of development at Novo Nordisk, said: “We are thrilled that Wigovy has been approved in the United States as the first treatment to help people manage their weight and reduce cardiovascular risk. ” he said. Said W.S.J.
Related: Novo Nordisk is worth more than Denmark’s GDP thanks to America’s Ozempic and Wegoby fads
The study also revealed a downside to Wegovy, with about a third of participants experiencing serious side effects. Approximately 17% of people who took Wegovy reportedly discontinued the study due to stomach-related issues such as nausea. Associated Press.
If an individual chooses to use Wegovy without insurance coverage in the U.S., Wegovy costs $1,349 per month
A recent study on weight-loss drugs found that a similar product from manufacturer Novo Nordisk, Ozempic (wegovy’s lower-dose version costs nearly $1,000 a month), returned at a much lower price than the current market price. It has been shown that it may be possible.
Researchers calculated Ozempic’s cost-based pricing, including profit margins, operating costs, and taxes, and found that prices ranged from $0.89 to $4.73 per month. This is much lower than the $935.77 Ozempic currently pays out of pocket in the US. .